Neurogene Inc.
NASDAQ:NGNEBiotechnology
+$0.76 today
- Market cap
- $365.03M
- Beta
- 2.04
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$4.42
Volume 0.28M
Average 0.16M
Returns on capital
Neurogene Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-34.1%
avg -25.9%
ROIC
-37.5%
avg -33.3%
ROA
-31.3%
avg -33.0%
Analysis
ROA is currently the strongest return metric at -31.3% versus its period average of -33.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Rachel L. McMinn | Founder, Executive Chair & Chief Executive Officer | USD 997.24K | 53 | — | — |
Christine Mikail Cvijic | President, CFO & Director | USD 874.06K | 48 | 84.04K | 0.53% |
Julie Jordan | Chief Medical Officer | USD 696.34K | 54 | 12.47K | 0.08% |
Stuart Cobb | Chief Scientific Officer | USD 478.81K | 55 | 30.50K | 0.19% |
Arvind Sreedharan | Senior Vice President of Business Operations | — | — | — | — |
Christina Shafer | Chief Commercial Officer | — | 50 | 120.00K | 0.76% |
Lina Li | Executive Director of Investor Relations | — | — | — | — |
Andrew E. Mulberg FAAP | Senior Vice President of Regulatory Affairs, Quality Assurance & Quality Control | — | — | — | — |
Donna Cochener-Metcalfe | Senior Vice President, General Counsel & Corporate Secretary | — | 51 | — | — |
Ricardo Jimenez | Senior Vice President of Technical Operations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 7, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
17
$1.13M
Net Transaction Value
−$1.13M
Net selling
Most Active
Cvijic Christine Mikail
12 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jul 7, 26Jul 7, 2026 | Cvijic Christine Mikail Direct | Sell | $151.8K$151,762.80 |
| Jul 6, 26Jul 6, 2026 | Cvijic Christine Mikail Direct | Sell | $21.6K$21,612.60 |
| Jul 2, 26Jul 2, 2026 | Cvijic Christine Mikail Direct | Sell | $87.5K$87,519.45 |
| Jul 2, 26Jul 2, 2026 | Cvijic Christine Mikail Direct | Sell | $53.9K$53,897.31 |
| Jul 1, 26Jul 1, 2026 | Cvijic Christine Mikail Direct | Sell | $25.2K$25,169.60 |
| May 6, 26May 6, 2026 | Cvijic Christine Mikail Direct | Sell | $144.4K$144,351.36 |
| May 6, 26May 6, 2026 | Cvijic Christine Mikail Direct | Sell | $155.7K$155,691.84 |
| Mar 26, 26Mar 26, 2026 | Cvijic Christine Mikail Direct | Sell | $55.3K$55,315.98 |
| Mar 26, 26Mar 26, 2026 | McMinn Rachel Direct | Sell | $74K$73,995.06 |
| Mar 26, 26Mar 26, 2026 | Jordan Julie Direct | Sell | $18.1K$18,127.57 |
1–10 of 17
Summary
Insiders reported 0 buys worth $0.00 and 17 sells worth $1.13M over the last 12 months. That adds up to net selling of $1.13M. Cvijic Christine Mikail was the most active insider with 12 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Neurogene Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about NGNE's management, answered from reported figures.
Who manages NGNE?
Neurogene Inc. (NGNE) lists 10 active executives. The top listed executive is Stuart Cobb, Chief Scientific Officer.
Are NGNE insiders buying or selling?
Recent insider activity shows net buying of $27.81M.
Continue the stock analysis
Jump to another research area for this company.